Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996060 · ClinicalTrials.gov registry record · Phase 1
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00996060 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 29 participants.
The verdict
NCT00996060, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
1. Primary Objective: The primary endpoint to this study will be to document the toxicities, and reversibility of toxicities, of this regimen of hydralazine and valproic acid in patients with advanced, unresectable, previously treated lung cancers, for whom no acceptable standard therapy is available. A primary endpoint will be to determine any potential dose limiting toxicities, and the Maximal Tolerated Dose of this regimen. 2. Secondary Objectives: The secondary endpoint of this study will be to determine any potential anti-tumor effects, as determined by the objective tumor response (complete and partial responses), clinical benefit (complete and partial responses, and clinical benefit), the time to tumor response, the time to tumor progression, and the overall survival.
Interventions
- DRUG Hydralazine and Valproic Acid: Cohort -1
- DRUG Hydralazine and Valproic Acid: Cohort 0
- DRUG Hydralazine and Valproic Acid: Cohort 1
- DRUG Hydralazine and Valproic Acid: Cohort 2
- DRUG Hydralazine and Valproic Acid: Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996060
The ClinicalTrials.gov registry entry for NCT00996060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydralazine and Valproic Acid: Cohort -1 is the first listed.
NCT00996060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996060 about?
NCT00996060 is a clinical study titled "Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies". 1. Primary Objective: The primary endpoint to this study will be to document the toxicities, and reversibility of toxicities, of this regimen of hydralazine and valproic acid in patients with advanced, unresectable, previously treated lung cancers, for whom no acceptable standard therapy is avai...
What is the current status of trial NCT00996060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00996060?
The interventions under investigation include: Hydralazine and Valproic Acid: Cohort -1 (DRUG), Hydralazine and Valproic Acid: Cohort 0 (DRUG), Hydralazine and Valproic Acid: Cohort 1 (DRUG), Hydralazine and Valproic Acid: Cohort 2 (DRUG), Hydralazine and Valproic Acid: Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT00996060?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.